GWPH News and Press, GW Pharmaceuticals Plc From 01/13/20

While most investors who are looking for marijuana stocks to buy tend to look at the bigger companies in the industry. This often denies the potential of the small to mid-cap players. These smaller companies have much to work with in terms of innovation. Within this young industry, innovation ...

Ahead of its JPM20 presentation, GW Pharmaceuticals (NASDAQ: GWPH ) announces preliminary 2019 results: More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Read more ...

- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex ® preliminary net product sales of approximately $104 million for the fourth quarter and approximately $296 million for t...

Last year was supposed to be when marijuana stocks proved their worth to Wall Street by translating substantial sales growth into recurring profits. Unfortunately for these companies, and their investors, it didn't work out as planned. Supply issues throughout Canada and high tax rates in a nu...

As we to move deeper into 2020, we continue to see the cannabis industry grow at a rapid pace. This is a mixture of new innovation and the public’s desire to see cannabis be legalized. There are many other factors within this, though currently, it seems that these two are the most promi...

It's pretty safe to say that last year did not go as planned for a majority of marijuana stock investors. The belief had been that cannabis stocks would push decisively into the green, led by skyrocketing dried cannabis sales in Canada, the subsequent launch of derivatives, and more legalizat...

LONDON and CARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief...

GW Pharmaceuticals (NASDAQ: GWPH) paved the way for modulating the cannabinoid pathway and turning that field of science into valuable prescription therapeutics. Over the past five years, GW transitioned from a promising idea to a commercial reality with two approved drugs in the U.S. and Eu...

We Are Selling Off Temporarily, But Still in a Larger Rally. As Scary as All This Talk of War Is, It Will Blow Over I made a case for the temporary nature of this sell-off on Friday. Rarely does even an actual war directly create a bear market condition, let alone a single drone strike. ...

Illinois is ringing in the new decade by becoming the 11th state in the country and the District of Columbia to allow the legal sale and purchase of marijuana. More news on: Aurora Cannabis Inc., Cronos Group Inc., Tilray, Inc., News on the U.S. economy, News on ETFs, Read more ...